Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT103 and Pembrolizumab in Refractory, Metastatic NSCLC
NCT05617313Phase 2Terminated
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GT103 in non-small cell lung cancer (NSCLC). Primary endpoints: Objective Response Rate up to 23 months and Frequency and Severity of Adverse Events. Started Feb 2023; status: terminated.
02
Drugs
GT103
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05617313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617313.